Trial site
Oncology Hematology West, PC dba Nebraska Cancer Specialists
- 12running trials
- 6closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Conditions
- Lung cancer5 trials
- Metastatic breast cancer5 trials
- Diffuse large B-cell lymphoma2 trials
- Prostate cancer2 trials
- Childhood cancers1 trial
- Chronic lymphocytic leukaemia1 trial
- Colorectal cancer1 trial
- Follicular lymphoma1 trial
- Gastric and oesophageal cancer1 trial
- Head and neck cancer1 trial
- Kidney cancer1 trial
- Neuroendocrine tumours1 trial
- Phase
- Phase 312 trials
- Phase 24 trials
- Phase 11 trial
- Phase 2/31 trial
- Status
- Active, not recruiting6 trials
- Recruiting6 trials
- Completed4 trials
- Terminated2 trials
- Lead sponsor
- Pfizer2 trials
- Seagen, a wholly owned subsidiary of Pfizer2 trials
- ALX Oncology Inc.1 trial
- Astellas Pharma Global Development, Inc.1 trial
- AVEO Pharmaceuticals, Inc.1 trial
- and 11 more
Running trials
Recruiting
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Recruiting
Active, not recruiting
Recruiting
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
Active, not recruiting
Active, not recruiting
Active, not recruiting
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Active, not recruiting
177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
Recruiting
Active, not recruiting
Recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Diffuse large B-cell lymphoma2 recruiting
- Chronic lymphocytic leukaemia1 recruiting
- Follicular lymphoma1 recruiting
- Gastric and oesophageal cancer1 recruiting
- Head and neck cancer1 recruiting
- Lung cancer1 recruiting
- Metastatic breast cancer1 recruiting
- Prostate cancer1 recruiting
Closed trials
Completed
Terminated
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
Completed
Completed
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
Terminated
Completed
Site data: ClinicalTrials.govUpdated 18 Nov 2026